Effects of half quantity CAG regimen combined with Decitabine in treatment of elderly patients with newly diagnosed acute myeloid leukemia
Objective:To observe effects of half quantity CAG regimen combined with Decitabine in treatment of elderly patients with newly diagnosed acute myeloid leukemia.Methods:A prospective study was conducted on 108 elderly patients with acute myeloid leukemia who were admitted to the hospital from January 2020 to January 2023.According to the random number table method,they were divided into control group and observation group,54 cases in each group.The control group was treated with Decitabine,while the observation group was treated with half quantity CAG regimen on the basis of that of the control group.The clinical remission rate,the hospitalization time,the T cell subset levels before and after the treatment,and the incidence of adverse reactions during hospitalization were compared between the two groups.Results:The clinical remission rate of the observation group was 72.22%(39/54),which was higher than 40.74%(22/54)of the control group,and the difference was statistically significant(P<0.05).The hospitalization time of the observation group was shorter than that of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD3+,CD4+and CD4+/CD8+in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Half quantity CAG regimen combined with Decitabine in the treatment of the elderly patients with acute myeloid leukemia can improve the clinical remission rate,shorten the hospitalization time,and reduce the levels of T cell subsets.Moreover,it is superior to single Decitabine treatment.
NETL
NSTL
万方数据
